High prevalence of myocardial monoclonal antimyosin antibody uptake in patients with chronic idiopathic dilated cardiomyopathy  by Obrador, Damià et al.
JACC Vol. 13. No. 6 1289 
May 19x9: 1289-93 
High Prevalence of Myocardial Monoclonal Antimyosin Antibody 
Uptake in Patients With Chronic Idiopathic Dilated Cardiomyopathy 
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Monoclonal antimyosin antibody studies were undertaken 
to assess the presence of myocardial uptake in patients with 
chronic idiopathic dilated cardiomyopathy. Three groups 
were studied: 17 patients with chronic (>12 months) idio- 
pathic dilated cardiomyopathy, 12 patients with a large, 
poorly contracting left ventricle not due to dilated cardio- 
myopathy (control patients) and 8 normal individuals. The 
patients in the cardiomyopathy and control groups showed 
a similar degree of clinical and functional impairment. 
Imaging was undertaken 48 h after antimyosin injec- 
tion. The heart/lung ratio of antimyosin uptake was used to 
assess the results. The mean ratio in the cardiomyopathy 
The clinical course of dilated cardiomyopathy is exceedingly 
variable. A few patients present an illness that resolves 
spontaneously or with immunosuppressive treatment: in 
others the illness evolves rapidly, within months, and the 
patient eventually dies or requires transplantation. Most 
patients follow a long-term clinical course. The natural 
history of dilated cardiomyopathy is that of a steady deteri- 
oration of functional class: the survival curves indicate a 
downhill course, especially during the first years after the 
diagnosis is made (1,2). 
The progressive nature of dilated cardiomyopathy has 
been explained as being a result of the long-term exhaustion 
of compensatory mechanisms initiated by a decrease in 
myocardial cell mass (3). However, necropsy studies in 
patients with this condition seldom reveal myocardial necro- 
sis (4): in fact. there is a striking lack of correlation between 
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group was 1.83 f 0.36 (range 1.40 to 2.80), a value 
significantly higher than that obtained in the control pa- 
tients without cardiomyopathy (mean 1.46 f 0.04, range 
1.38 to 1.50) or normal subjects (mean 1.46 f 0.13, range 
1.31 to 1.6) (p < 0.01). No difference in the ratio was noted 
between the normal subjects and control patients. Abnor- 
mal antimyosin uptake was seen in 12 (70%) of the 17 
patients with cardiomyopathy and in only 1 (8%) of the 12 
control patients. Positive monoclonal antimyosin antibody 
studies are highly prevalent in chronic idiopathic dilated 
cardiomyopathy. 
(J Am Co11 Cardiol1989;13:1289-93) 
the microscopic findings and the degree of cardiac dysfunc- 
tion in patients with end-stage dilated cardiomyopathy (3). 
Monoclonal antimyosin antibodies labeled with indium- 
1 I1 have been useful in detecting active myocyte damage. 
When disruption of myocardial cell membrane occurs, this 
antibody specifically binds to the exposed myosin, and 
myocardial uptake is detected (5-8). This technique has been 
useful to diagnose active myocyte damage in acute myocar- 
dial infarction, acute myocarditis and acute cardiac rejection 
(9-12). In the present investigation, antimyosin studies were 
undertaken to assess the presence of myocardial uptake in 
patients with chronic idiopathic dilated cardiomyopathy. 
Methods 
Study patients. Three groups were studied with antimyo- 
sin: 8 healthy individuals (normal group) I7 patients with 
chronic idiopathic dilated cardiomyopathy (study group) and 
I2 patients with a large, poorly contracting left ventricle not 
due to dilated cardiomyopathy (control group). 
Normal healthy individuals. Eight men aged 28 to 38 
years (mean 32 it 3), were selected for the normal group. 
Clinical data showed absent cardiac signs or symptoms; and 
normal physical findings, electrocardiogram (ECG) and 
chest roentgenogram; a two dimensional echocardiographic 
study disclosed a normal heart in each subject. 
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Table 1. Clinical Features and Detection of Myocyte Damage in Patients With Chronic Idiopathic 
Dilated Cardiomyopathy 
Patient 
No. 
Age (yr) 
& Gender 
Onset of 
CHF (mo) EF (%I Biopsy 
Antimyosin Uptake 
Visual Heart/Lung Ratio 
2 
3 
4 
5 
6 
1 
8 
9 
IO 
II 
12 
13 
I4 
I5 
I6 
17 
52M 84 
42M 38 
46F 48 
34F 36 
40F 60 
35M 52 
49M 25 
39M 13 
38F 36 
5lM 40 
42M 108 
53M 40 
4lM 48 
37M 48 
48F 33 
56M 84 
5lM 36 
28 
25 
40 
20 
23 
28 
23 
32 
31 
45 
20 
52 
54 
32 
28 
26 
1.90 
2.80 
I .76 
I .50 
2.16 
2.22 
I .89 
2.00 
I .60 
1.40 
1.70 
1.50 
1.50 
1.55 
1.60 
2.20 
I .80 
*Poor quality echocardiogram for measurements. CHF = duration of signs or symptoms of congestive heart 
failure: EF = echocardiographic left ventricular ejection fraction: - = negative for myocarditis; (t) = positive for 
myocarditis. 
Patients with chronic idiopathic dilated cardiomyopathy. 
During a 14 month interval (January 1987 to March 1988) 30 
patients with idiopathic dilated cardiomyopathy were stud- 
ied with antimyosin. Thirteen patients were excluded: six 
patients who had had an acute or subacute (< 1 year) clinical 
course, two with past myocarditis and spontaneous recov- 
ery, four with a history of alcoholism and one patient with 
isolated right ventricular cardiomyopathy. Only patients 
with a clinical history > 12 months were included. Therefore, 
a total of 17 patients, 12 men and 5 women, aged 34 to 56 
years (mean 44 ? 7), formed the study group (Tables 1 and 
2). Signs or symptoms of heart failure had been detected 13 
to 108 months (mean 48 5 24) before inclusion, and patients 
had been followed up in the outpatient clinic for 1 to 108 
months (mean 26 t 30). At the time of antimyosin study all 
patients were in a stable state. Their functional classifica- 
tion, ventricular end diastolic diameter and ejection fraction 
assessed by two-dimensional echocardiography are shown in 
Tables 1 and 2. Cardiac catheterization showed normal 
coronary arteries in every patient. Right ventricular biopsy 
was undertaken with use of a Cordis bioptome (13); four to 
eight samples were taken. Biopsy interpretation for myocar- 
ditis followed the Dallas criteria (14). 
Patients with a large left ventricle not due to cardiomyop- 
athy (control group). Twelve patients, 10 men and 2 women 
aged 29 to 72 years (mean 49 2 12) with left ventricular 
dilation and low ejection fraction due to causes other than 
dilated cardiomyopathy, were studied with antimyosin. 
Angiographically proved coronary heart disease was present 
in 10 and valvular heart disease in 2. To minimize the 
possibility of detecting myocardial uptake secondary to 
myocardial ischemia, patients with a history of chest pain 
~12 months before antimyosin study were excluded. 
The clinical and echocardiographic features of patients in 
Table 2. Clinical and Echocardiographic Features of Patients With 
Chronic Idiopathic Dilated Cardiomyopathy and Control Patients* 
Age (yr) 
Mean 
Range 
NYHA class 
I 
2 
3 
4 
LVDD (mm) 
Mean 
Range 
LVEF (%) 
Mean 
Range 
Patients 
With Dilated 
Cardiomyopathy Control Group 
(n = 17) (n = 12) Significance 
44 ? 7 49 + I2 NS 
34 to 52 29 to 72 
I (6%) 0 
II (65%) 4 (33%) 
4 (23%) 7 (58%) 
I (6%) I (8%) 
76% I5 68 ? 5 NS 
52 to 113 60 to 76 
31 ? IO 29 + 5 NS 
20 to 54 22 to 37 
*Control patients are those with a dilated poorly contracting left ventricle 
not due to dilated cardiomyopathy. NYHA = New York Heart Association 
functional class: LVDD = left ventricular diastolic diameter: LVEF = left 
ventricular ejection fraction; NS = difference not significant. 
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the control and cardiomyopathy groups are compared in 
Table 2. The patients in these two groups were older than the 
normal individuals; no other clinical or functional differences 
between groups were noted. 
After giving informed consent, patients and subjects 
received an intradermal injection of 0.1 ml of labeled anti- 
body; skin tests were negative in all patients studied; 30 min 
later patients received an intravenous injection of 0.5 mg of 
RI IDIO-Fab-DTPA labeled with 2 mCi of indium-I I1 (Cen- 
tocor). Imaging and interpretation of the studies were per- 
formed according to our previously described protocol (15). 
Planar scintigraphic images were obtained 48 h after antimy- 
osin injection. Imaging was undertaken in anterior and left 
anterior oblique projections with use of a conventional large 
field of view camera with a high resolution medium energy 
collimator and 20% window centered on 247 and 173 keV 
peaks. A minimum of 500,000 counts was collected in 5 to 10 
min. Analog and digital images collected in a 128 x 128 
matrix were stored for subsequent analysis. 
Interpretation of the isotopic studies (Fig. 1). This was 
performed by two experienced observers who did not know 
the results of the biopsy or clinical data. 
Visrrcrl i~zterpctr~tion. A visual score derived from analog 
images read from the unprocessed gray scale monitor display 
was used: 0 ; no myocardial uptake: 1 = mild or faint 
uptake: 2 = clear but moderate uptake: 3 = intense uptake. 
A hecrrtllu~~~ rritio. The digital unprocessed anterior pro- 
jection was used to adjust a region of interest in the myo- 
cardium and a region of interest in each lung. Average 
counts per pixel in the myocardium were divided by average 
counts per pixel in the lungs to obtain the final ratio. 
Interobserver and intraobserver variability and reproducibil- 
ity of this ratio have been previously assessed (15). 
Statistical analysis. One-way analysis of variance and the 
Student’s t test were used to analyze differences between 
pairs of groups. The Statistical Package for Social Sciences 
(SPSSiPC) program was used for analysis of the data. 
Results 
Tracer distribution of antimyosin in the normal group. At 
48 h. no tracer distribution within the cardiac region was 
usually seen; occasionally. a faint signal in the lower left 
parasternal region could be detected (score 0 to 1) (Fig. IA). 
The heart/lung ratio was 1.46 ? 0.04 (1.38 to 1.50) (Fig. 2). 
Antimyosin in dilated cardiomyopathy and control groups. 
Mean heart/lung ratio in the cardiomyopathy group was I .83 
-t 0.36 (range 1.40 to 2.80); this ratio was higher than the 
ratio obtained in the control group (1.46 r 0.15, range 1.26 to 
1.80) or in the normal group (1.46 ? 0.04, range 1.38 to I JO) 
(p < 0.01) (Fig. 2). No difference was noted between the 
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Figure 1. Interpretation of antimyosin studies. A, No uptake in the 
cardiac area in a normal subject; uptake by the liver and upper 
region of both kidneys is seen. B, Important antimyosin uptake 
(visual score 3) in a patient with chronic dilated cardiomyopathy; 
arrows indicate the cardiac uptake border. C, Moderate uptake 
(visual score 2) in a patient with chronic dilated cardiomyopathy. D, 
Calculation of the heart/lung ratio of the study shown in C; isotopic 
activity in the cardiac area is divided by the activity in different 
pulmonary areas of interest to obtain an averaged heart to lung ratio. 
normal and the control group. Visual score was I .65 t 1 .O in 
the cardiomyopathy group (Fig. 1B and C) and 0.50 +- 0.67 in 
the control group (p < 0.001); no difference in visual score 
was observed between the normal and the control groups. 
Positive antimyosin studies, taking a ratio > I .58 as a cutoff 
point (mean ratio in the normal group + 3 SD). was seen in 
12 (70%) of the I7 patients with cardiomyopathy and in only 
I (8%) of the 12 control patients. 
Endomyocardial biopsy in dilated cardiomyopathy. Only 1 
of the 17 patients with dilated cardiomyopathy fulfilled the 
diagnostic pathologic criteria for myocarditis (Patient 3, 
Table I). The antimyosin study showed an abnormal uptake 
(ratlo I .76. visual estimation 2). 
Discussion 
Antimyosin uptake in dilated cardiomyopathy. The pres- 
ent report is the first to describe antimyosin studies in a 
group of patients with stable chronic idiopathic dilated 
cardiomyopathy. Our results indicate that 1) there is a high 
prevalence of antimyosin uptake in such patients, and 2) 
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NORMAL DCM CONTROL 
t7=8 n=17 n=12 
Figure 2. Antimyosin uptake in the three study groups. Normal = 
normal individuals; DCM = patients with chronic idiopathic dilated 
cardiomyopathy; Control = patients with end-stage heart disease 
not due to dilated cardiomyopathy. 
positive studies are not due to left ventricular dilation or to 
the consequences of heart failure, as a similar cardiac 
impairment was present in the control group of patients with 
left ventricular dilation and dysfunction. Only one patient in 
the control group, with coronary heart disease, showed mild 
positive antimyosin uptake; he died suddenly 3 weeks after 
the antimyosin study, and it is possible that myocardial 
ischemia, despite our care in selecting control patients 
without chest pain, could be responsible for this finding (16). 
Antimyosin uptake to detect active myocyte damage. Myo- 
cardial uptake of antimyosin in patients with chronic dilated 
cardiomyopathy probably reflects the presence of active 
myocyte damage, despite the fact that endomyocardial bi- 
opsies revealed myocyte damage in only 1 of 17 patients. A 
similar discrepancy has been described in myocarditis and 
cardiac transplantation (l&12,15). In the present group of 
patients, it is not clear whether myocardial uptake reflects a 
diffuse cellular damage undetected by microscopy or a false 
positive isotopic study. An excellent clinical model to shed 
light on this question can be provided by antimyosin studies 
performed after cardiac transplantation. In a recent study, 
we (12) demonstrated that soon after transplantation, pa- 
tients invariably show antimyosin uptake that gradually 
decreases during the first few months. By 1 year after 
transplantation, some patients have a negative and others a 
positive scan; in subsequent biopsies, the former do not 
manifest rejection, whereas cell damage can be detected in 
the latter patients at some stage during biopsy follow-up 
(unpublished observations). Interestingly, the heart/lung ra- 
tios of patienfs after cardiac transplantation are similar to 
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those seen in our current study group of patients with 
chronic stable dilated cardiomyopathy. 
Clinical and prognostic implications. The implications of 
myocardial uptake of antimyosin are only speculative. It was 
recently suggested (3) that dilated cardiomyopathy is a 
common pathway of many diverse end-stage heart diseases, 
including valvular and coronary disease. However, the high 
prevalence of antimyosin uptake in patients with dilated 
cardiomyopathy compared with that in patients with other 
types of end-stage heart disease indicates that dilated car- 
diomyopathy may be a distinct clinical condition. This would 
reinforce the definition of dilated cardiomyopathy as an 
idiopathic muscle disease of unknown origin not secondary 
to coronary, valvular or congenital heart disease (17). 
The prognostic sigmjicance of antimyosin uptake in pa- 
tients with chronic dilated cardiomyopathy is uncertain. 
Several clinical series (1,2) of such patients have shown the 
progressive nature of the disease. Recently, Diaz et al. (2) 
provided a fine description of the natural history of a very 
large series of these patients: their study revealed that the 
probability of survival steadily decreases during the first 4 
years after the diagnosis, and a certain plateau is attained 
thereafter. The present study identified patients who have 
antimyosin uptake and those who have a negative scan. It is 
tempting to correlate these patterns of myocardial antimyo- 
sin uptake with clinical outcome; possibly, continual myo- 
cardial uptake could explain the steady clinical deterioration 
in some patients with dilated cardiomyopathy and the stable 
course in others without such activity. 
Interruption of this myocardial lesional activity could be 
considered. Although further studies are needed to address 
this problem, it is possible that patients with dilated cardio- 
myopathy and a positive antimyosin study might respond to 
some form of therapy (for example, immunosuppression) 
directed to halting such activity, whereas those with absent 
uptake would not. 
We are grateful to H. William Strauss, MD, Ban An Khaw, PhD and 
Tsunehiro Yasuda, MD of the Massachusetts General Hospital for their 
helpful comments on the mechanism of antimyosin uptake, and to Gaieta 
Permanyer, MD and Valentin Fuster, MD for critical review of the manu- 
script. 
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